Skip to Main Content

The Food and Drug Administration on Wednesday approved a new drug to treat patients with multiple myeloma, overruling a panel of outside cancer experts who expressed concerns about its toxicity.

The new multiple myeloma drug, called selinexor, will be marketed by Karyopharm Therapeutics under the brand name Xpovio.


The FDA cleared Xpovio under an accelerated, or conditional, approval based on a single-arm clinical trial showing a 25% tumor response rate. The patients enrolled in the clinical trial had advanced multiple myeloma no longer responsive to at least four prior therapies. 

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • For Chris sake if you’re dying from MM whats the hell! Maybe the studies will lead to less toxic version so your children ‘s childrens will survive! Thank you Mr Trump for giving us the opportunity to choose our own destiny and not the FDA…

    • My understanding is that some patient deaths during the trials were attributed to the toxicity of the drug. A drug ain’t much good if it kills you before it cures you.

Comments are closed.